Conversion from Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients with Risk Factors

Shuming Ji, Jiqiu Wen, Dongrui Cheng, Qiquan Sun, Jinsong Chen, Zhihong Liu

.

DOI: 10.4236/ojots.2011.11002                

Abstract

Background: The efficacy and safety of conversion treatment with sirolimus in renal transplant recipients using the calcineurin inhibitor (CNI) with one or more risk factors was evaluated. Methods: Ninety-three renal transplant recipients were prospectively enrolled. CNIs(CsA and FK506) as main immunosuppressant were converted to SRL immunosuppressant protocol. Rapid conversion with si-rolimus was performed in all patients. The CNI withdrawal was in 2 weeks. At 4 hours after oral administration of cyclosporin A or tacrolimus, the patients took sirolimus. Initial dose of sirolimus was 6 mg, and repeated maintenance dose is 1.0 - 2.0 mg/d. The first concentration of sirolimus was detected at 5 - 7 days after first oral administration, and the target concentration was 6 - 10 μg/L. Results: The symptoms were markedly improved in patients with CNI induced renal toxicity and CNI induced liver toxicity, and the concentration of sirolimus were maintained at (5.1 ± 1.2) μg/L. Serum creatinine levels decreased from (297.72 ± 150.28) μmol/L to (123.76 ± 44.2) μmol/L, and the liver function were recovery in 24 (92.3%) patients. 9 patients with high glucose returned to normal, and 2 patients were improved. Serum creatinine levels decreased more than 25% of primary level in 17 patients, and the effective rate was 51.5%. 10 patients with tumor were appeared 6 - 43 months after renal transplantation, no recurrence was found in 8 of them and 2 patients were dead. Acute rejections were occurred in 3 patients at 6 months after conversion treatment. The complications were included hyperlipidemia and proteinuria. 3 patients were dead, 6 patients returned to dialysis treatment, and 2 patients were removal of grafts. At 3 years after conversion treatment, the survival rates of patients and grafts were 90.9% and 75.8%, respectively. Conclusion: The conversion treatment with SRL and MMF may be a better option for the renal transplant recipients using the CNI with risk factors appeared.

Keywords

Renal Transplant, Calcineurin, Inhibitor, Conversion, Sirolimus

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	L. Li and Q. Sun, “Renal transplantation in China: Ten Years of Experience at Nanjing Jinling Hospital,” Clinical Transplants, Vol. 1, No. 5, 2006, pp. 71-77.
[2]	A. Magnasco, A. Rossi, P. Catarsi, R. Gusmano, F. Ginevri, F. Perfumo and G. M. Ghiggeri, “Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives,” Current Clinical Pharmacology, Vol. 3, No. 3, 2008, pp. 166-173. doi:10.2174/157488408785747674
[3]	D. W. Hanto and R. Chudzinski, “What Does the CONVERT Trial Really Tell Us about Conversion from Calcineurin Inhibitors to Sirolimus?” Transplantation, Vol. 87, No. 2, 2009, pp. 164-165. doi:10.1097/TP.0b013e318192790f
[4]	J. R. Chapman, “Chronic Calcineurin Inhibitor Nephrotoxicity-Lest We Forget,” American Journal of Trans-plantation, Vol. 11, No. 4, 2011, pp. 693-697. doi:10.1111/j.1600-6143.2011.03504.x
[5]	R. Pfitzmann, J. Klupp, J. M. Langrehr, M. Uhl, R. Neuhaus, U. Settmacher, T. Steinmüller and P. Neuhaus, “Mycophenolatemofetil for Immunosuppression after Liver Transplantation: A Follow-up Study of 191 Patients,” Transplantation, Vol. 76, No. 1, 2003, pp. 130-136. doi:10.1097/01.TP.0000071522.74885.48
[6]	D. R. Kuypers, K. Claes, B. Bammens, P. Evenepoel and Y. Vanrenterghem, “Early Clinical Assessment of Glucose Metabolism in Renal Allograft Recipients: Diagnosis and Prediction of Post-Transplant Diabetes Mellitus (PTDM),” Nephrology Dialysis Transplantation, Vol. 23, No. 6, 2008, pp. 2033-2042. doi:10.1093/ndt/gfm875
[7]	K. Solez, R. B. Colvin, L. C. Racusen, B. Sis, P. F. Hal-loran, P. E. Birk, P. M. Campbell, M. Cascalho, A. B. Collins, A. J. Demetris, C. B. Drachenberg and I. W. Gib-son, “Banff 05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allo-graft Nephropathy (‘CAN’),” American Journal of Transplantation, Vol. 7, No. 3, 2007, pp. 518-526. doi:10.1111/j.1600-6143.2006.01688.x
[8]	J. C. Ruiz, A. Alonso, M. Arias, J. M. Campistol, M. G. Molina, J. M. G. Posada, J. M. Grinyo, J. M. Morales, F. Oppenheimer, A. Sánchez Fructuoso and J. Sán-chezPlumed, “Conversion to Sirolimus,” Nefrologia, Vol. 26, No. 2, 2006, pp. 52-63.
[9]	S. M. Ji, L. S. Li, J. Q. Wen, G. Z. Sha, Z. Cheng, D. R. Cheng, J. S. Chen and Z. H. Liu, “Therapeutic effect of Tripterygium Wilfordii Hook f. on Proteinuria Associated with Sirolimus in Renal Transplant Recipients,” Transplant Proceedings, Vol. 40, No. 10, 2008, pp. 3474-3478. doi:10.1016/j.transproceed.2008.07.140
[10]	W. Ji-qiu and J. Shuming, “Alleviation of Calcineuron Inhibitorinduced Nephrotoxicity with Rapamycin,” Chinese Journal of Nephrology Dialysis & Transplantation, Vol. 16, No. 3, 2007, pp. 283-288.
[11]	J. Shu-ming, W. Ji-qiu, S. Guo-zhu, C. Dong-rui, S. Qi-quan, C. Jin-Song, L. Zhi-hong and L. Lei-shi, “Conversion Treatment with Sirolimus in Renal Transplant Recipients,” Journal of Clinical Rehabilitative Tissue Engineering Research, Vol. 13, No. 31, 2009, pp. 6019-6022.
[12]	A. Gürkan, S. Kacar, U Erdogdu, C Varilsüha, G. Kandemir, C. Karaca and F. Akman, “The Effect of Sirolimus in the Development of Chronic Allograft Nephropathy,” Transplant Proceedings, Vol. 40, No. 1, 2008, pp. 114-116. doi:10.1016/j.transproceed.2007.11.005
[13]	S. M. Ji, L. S. Li, G. Z. Sha, J. S. Chen and Z. H. Liu, “Conversion from Cyclosporine to Tacrolimus for Chronic Allograft Nephropathy,” Transplant Proceedings, Vol. 39, No. 5, 2007, pp. 1402-1405. doi:10.1016/j.transproceed.2006.11.030
[14]	J. M. Campistol, J. Albanell, W. Arns, I Boletis, J. Dantal, J. W. de Fijter, S. A. Mortensen and H. H. Neumayer, “Use of Proliferation Signal Inhibitors in the Management of Post-Transplant Malignancies-Clinical Guidance,” Nephrology Dialysis Transplantation, Vol. 22, No. S1, 2007, pp. i36-i41. doi:10.1093/ndt/gfm090
[15]	M. Schubert, RVenkataramanan, D. W. Holt, L. M. Shaw, W. McGhee, J. Reyes, S. Webber and R. Sindhi, “Phar-macokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients,” American Journal of Transplantation, Vol. 4, No. 5, 2004, pp. 767-773. doi:10.1111/j.1600-6143.2004.00411.x
[16]	X. Y. Qiu, Z. Jiao, M. Zhang, L. J. Zhong, H. Q. Liang, C. L. Ma, L. Zhang and M. K. Zhong, “Association of MDR1, CYP3A4*18B, and CYP3A5*3 Polymorphisms with Cyclosporine Pharmacokinetics in Chinese Renal Transplant Recipients,” European Journal of Clinical Pharmacology, Vol. 64, No. 11, 2008, pp. 1069-1084. doi:10.1007/s00228-008-0520-8